MAM
MACK

Meeder Asset Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Meeder Asset Management’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-70
Closed -$1K – 1920
2017
Q3 		$1K Sell
70
-134
-66% -$1.41K ﹤0.01% 1607
2017
Q2 		$2K Hold
204
– – ﹤0.01% 1484
2017
Q1 		$5K Buy
204
+48
+31% +$1.2K ﹤0.01% 1132
2016
Q4 		$5K Buy
+156
New +$6.65K ﹤0.01% 872

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Meeder Asset Management's MACK Position: Q4 2017 in Review

Meeder Asset Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2017, closing a stake of 70 shares — an estimated $1K sold.

Meeder Asset Management first reported a position in MACK in Q4 2016 and held it in 4 quarters. The position peaked at $5K in Q1 2017. 78 funds tracked by Wall St. Rank hold MACK as of Q4 2017.

  • Meeder Asset Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Meeder Asset Management sold 70 Merrimack Pharmaceuticals, Inc. shares in Q4 2017, an estimated $1K.
  • Meeder Asset Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2016 and held it in 4 quarters.
  • Meeder Asset Management's Merrimack Pharmaceuticals, Inc. position peaked at $5K in Q1 2017.
  • 78 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2017.

Based on Meeder Asset Management's 13F filing for Q4 2017, filed 2 Feb 2018.